NIH | National Cancer Institute | NCI Wiki  

Versions Compared

Old Version 1

changes.mady.by.user Kuffel, Gina (NIH/NCI) [C]

Saved on

compared with

New Version 2

changes.mady.by.user Kuffel, Gina (NIH/NCI) [C]

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

...

  •  Debbie to work with Ralph to write invitation for Jaime Modiano
  •  Gina to speak with Debbie to arrange a meeting with Gerry to discuss data submission (Toby, Debbie, Phil)
  •  Revisit new steering committee members in September (loop Connie into this discussion) 

Agenda

ItemWhoTalking Points
Continue discussion of potential submission of FidoCure  Animal Health data

Debbie Knapp

  • We asked FidoCure if they had data on glioma, osterosarcoma, bladder cancer, mucosal and acral melanoma, and mast cell tumor.

    • Gerry Post replied “We do have data on osteosarcoma, mast cell tumors and some acral melanomas. As for gliomas and urothelial carcinomas, biopsies are much less common so we have less data.” Although he does not specify, I would think they would have lots of data on mucosal oral melanoma too.
    • If we want to pursue this further, I think Gerry would like a more specific request that he will then take to his board.
Potential collaboration with the Data for the Common Good (DCG) team and possibly a new working group

Kim, Erika (NIH/NCI) [E] 

Discussion with FidoCure

Dr. Gerald Post, Chief Medical Officer at FidoCure

Ben Toussant, Vice President of Operations at FidoCure

  • Goals of the ICDC
  • Types of data that FidoCure has
  • Potential collaborations
  • Data submissions
New ICDC Subcommittee: Cross-Species Mapping Committee (CSMC)

Purpose: Facilitation of human-canine comparative data analysis from the ICDC and other nodes in the CRDC using interoperability components such as Cancer Data Aggregator and aligning with data standards

All

DCG are interested in helping end users identify related cases between canine and pediatric oncologyBuilding
    • consensus data standards between human and canine data elements
    • Mapping existing data elements in the ICDC to
NCIT codes
    • caDSR II to facilitate the findability of canine data related to human data through platforms such as the Cancer Data Aggregator.
  
    •  
  • How can we leverage a potential collaboration with Data for the Commons Good (DCG) team?
    • The DCG team is in the process of mapping data elements from the Pediatric Cancer Data Commons to caDSRII and is willing to work with us to share common data elements CDEs

New ICDC Subcommittee: Longitudinal Data Acquisition and Use Committee (LDAUC)

Purpose: Formulate scientific questions and use cases that can be used to interrogate longitudinal datasets that would justify the ingestion of such data into the ICDC.. 

All

DGAB Updates

Kuffel, Gina (NIH/NCI) [C] 

Recently Released

ICDC Studies in Active Submission

  • COTC021
    • Approved by SAC on 6/30/23
    • "Evaluation of Orally Administered mTOR inhibitor Rapamycin in Dogs in the Adjuvant Setting with Osteosarcoma"
    • Dr. Amy LeBlanc
    • Status: Working with data submitters to provide AWS creds
BPSC Updates
New ICDC Bioinformatics Tutorial Website

Kuffel, Gina (NIH/NCI) [C] 

  • Should we repurpose the Best Practices Subcommittee to form the new Data Standardization Team?
  • Should we create an outline of the goals and some next steps for aligning canine data properties and values to a controlled vocabulary?
    • ICDC Biospecimen Data

    Kuffel, Gina (NIH/NCI) [C] 

    Which controlled vocabularies should we consider (NCIT, SnoMed, etc.)
    Upcoming Steering Committee Meeting

    Ralph Parchment

    December
    • January meeting:
    12/15/23
    •  
    • Ralph will send out the minutes for approval

    Minutes (Not Verbatim)

    TH - Golden Retriever Lifetime study has contacted us with biospecimen data, they would like a discussion. Could we have a page within the application to redirect users to biospecimen data? We could let them know about the potential for displaying URLs for their biospecimen data. We could organize this data by type (ie. plasma, mast cell, circulating tumor cells, etc.), we could provide contact information at the consortium level).

    ...

    8. Develop biomarkers of response and resistance in humans by analyzing the responses and genomic signatures in dogs.

    Action items

    •  Gina to speak with Debbie to arrange a meeting with Gerry to discuss data submission (Toby, Debbie, Phil)
    •  Toby to invite Greg from CCDI to the next Executive Team Meeting in January
    •  Toby to look across the NCI directory to find person that has a combination of canine and pediatric oncology background